EMPAGLIFLOZIN IS MORE EFFECTIVE IN REDUCING MICROALBUMINURIA AND ALT LEVELS COMPARED WITH DAPAGLIFLOZIN: REAL LIFE EXPERIENCE

Gunhan H. G., Imre E., Erel P., Ustay Ö.

ACTA ENDOCRINOLOGICA-BUCHAREST, cilt.16, sa.1, ss.59-67, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4183/aeb.2020.59
  • Dergi Adı: ACTA ENDOCRINOLOGICA-BUCHAREST
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE
  • Sayfa Sayıları: ss.59-67
  • Anahtar Kelimeler: SGLT2 inhibitors, Type 2 diabetes mellitus, HbA1c, Body mass index, Weight loss, Real life experience, TYPE-2 DIABETES-MELLITUS, SERUM URIC-ACID, SGLT2 INHIBITOR, BODY-COMPOSITION, GLYCEMIC CONTROL, OUTCOMES, METAANALYSIS, REDUCTION, TRANSPORT, WEIGHT
  • Marmara Üniversitesi Adresli: Evet

Özet

Context. Sodium Glucose Co-Transporter-2 inhibitors (SGLT2i) are oral antidiabetic agents that can be used with insulin in the treatment of type 2 diabetes mellitus, known for cardiovascular and renal benefits. Dapagliflozin and empagliflozin are available in Turkey and we aimed to evaluate real-life data of using these two molecules with other oral antidiabetic drugs (OAD) or insulin.